In a filing, Phathom Pharmaceuticals Inc revealed its CFO and CBO Henderson Molly unloaded Company’s shares for reported $38128.0 on Apr 08 ’24. In the deal valued at $11.10 per share,3,435 shares were sold. As a result of this transaction, Henderson Molly now holds 95,263 shares worth roughly $0.96 million.
Then, Curran Terrie sold 16,851 shares, generating $153,513 in total proceeds. Upon selling the shares at $9.11, the President and Chief Executive now owns 410,784 shares.
Before that, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares. Phathom Pharmaceuticals Inc shares valued at $29,999,994 were divested by the 10% Owner at a price of $8.10 per share. As a result of the transaction, TAKEDA PHARMACEUTICAL CO LTD now holds 3,755,583 shares, worth roughly $37.71 million.
Stifel initiated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on May 03, 2024; the price target was $24. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering PHAT with “Buy” recommendation on August 09, 2023. Evercore ISI revised its rating on May 11, 2023. It rated PHAT as “an Outperform” which previously was an “an In-line”.
Price Performance Review of PHAT
On Friday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock jump 2.87% to $10.04. Over the last five days, the stock has gained 9.37%. Phathom Pharmaceuticals Inc shares have risen nearly 9.97% since the year began. Nevertheless, the stocks have fallen -13.60% over the past one year. While a 52-week high of $17.02 was reached on 04/09/24, a 52-week low of $6.07 was recorded on 02/13/24. SMA at 50 days reached $9.78, while 200 days put it at $10.02. A total of 0.65 million shares were traded, compared to the trading of 1.08 million shares in the previous session.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 9.80, which if violated will result in even more drops to 9.55. On the upside, there is a resistance level at 10.33. A further resistance level may holdings at 10.61. The Relative Strength Index (RSI) on the 14-day chart is 55.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.32, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 20.25%. Stochastics %K at 55.29% indicates the stock is a holding.
The most recent change occurred on March 13, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
